MedTrace Logo

The Effect of Position on Urge Sensation in Volunteers and in Patients With Overactive Bladder Syndrome

NCT00821314 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2010-06-16

No results posted yet for this study

Summary

Importance of the problem OAB is a common health problem. Milsom et al. \[1\] randomly selected a population from six European countries. From this population, 17% of the respondents reported having OAB symptoms with 14% reporting frequency, 9% urgency, and 6% urge incontinence. The study by Milsom et al. \[1\] showed that OAB adversely affected the lives of the majority (65%) of the respondents who reported OAB symptoms. Chen et al. \[2\] also reported that the prevalence of OAB in Taiwanese women was similar to that of Western women. In the study of Chen et al.\[2\], the prevalence of OAB was 18.6% for the patients; perceptions and the number of OAB condition significantly increased in the elderly women (over 65 years old, 39.3%). Apart from impairing the physical health, OAB may have a tremendous effect on psychological and social well-being. Information on the symptoms and disease severity can yield important information that often complements objective measures.

Incontinence, increased urge and increased frequency of micturition affect nearly 100 million people in the western world (33 million in the US and 66 million in the European Union). These conditions are not life threatening but they seriously affect quality of life and ability to work. OAB is in some studies reported to have an incidence of up to 17 % in the western population with great consequences for the quality of life.

Economic cost The total economic cost of this group of conditions is high. In 2002 the costs in the US were approximately $12.7 billion\[1\] (estimated to be $17 billion and €22 billion/year in 2005). Approximately 25% of this expenditure is spent on treatment (drug therapy, clinical consultation and surgery). Of those who suffer only 28% have sought help and only half of those currently receive treatment. Less than 3% regain long lasting normal control. Therefore, these costs are an under-estimate and the problem is large.

Aetiology

Conditions

  • Overactive Bladder Syndrome

Sponsors & Collaborators

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Mohammad S Rahnama'i', MD · University hospital Maasticht

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00821314 on ClinicalTrials.gov